This is an old revision of this page, as edited by 80.161.78.4 (talk) at 14:04, 26 January 2009. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 14:04, 26 January 2009 by 80.161.78.4 (talk)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff){{Drugbox | IUPAC_name = (3S)-3-{carbamoyl}-3-formamido}butanamido]-3-carboxypropanamido]-3-propanamido]-3-hydroxybutanamido]acetamido}-3-(1H-indol-3-yl)propanamido]-4-(methylsulfanyl)butanamido]propanoic acid | image = Ceruletide.png | CAS_number = 17650-98-5 | ATC_prefix = V04 | ATC_suffix = CC04 | PubChem = 16219178 | DrugBank = | C=58|H=73|N=13|O=21|S=2 | molecular_weight = 1352.40 g/mol | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = }}
Ceruletide (or Caerulein) is a specific decapeptide obtained from the skin of Litoria caerulea, an Australian amphibian. Caerulein is similar in action and composition to cholecystokinin. It stimulates gastric, biliary, and pancreatic secretion; and certain smooth muscle. It is used in paralytic ileus and as diagnostic aid in pancreatic malfunction.
This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it. |